


CLAIMS

1. A compound of formula (I):



10 R^1 is independently hydrogen, C_{1-6} alkyl or C_{3-6} cycloalkyl;

R^2 is independently aryl, heteroaryl or a group $C_{1-6}alkylR^9$, $CO(C_{1-6}alkyl)R^9$ or $SO_2(C_{1-6}alkyl)R^9$;

15 or R^1 and R^2 together with the nitrogen atom to which they are attached form a 4 to 7-membered saturated ring optionally containing a carbonyl group, O, S or N atom and optionally substituted by one or more C_{1-6} alkyl, amino, hydroxy, $CO_2C_{1-6}alkyl$, $COC_{1-6}alkyl$, halogen, $C_{1-6}alkylhydroxy$, $NR^{10}R^{11}$ where R^{10} and R^{11} are independently hydrogen, C_{1-6} alkyl or together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated ring optionally containing a further O, S or NR^1 group, C_{1-6} alkyl, $NR^{12}R^{13}$ where R^{12} and R^{13} are independently hydrogen or C_{1-6} alkyl, $CONR^{12}R^{13}$, or optionally substituted by $C_{1-6}alkylR^9$, aryl, phenoxy, $COaryl$, $COheteroaryl$ or a heteroaryl group, the latter six groups being optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, $CONR^{12}R^{13}$, $SO_2NR^{12}R^{13}$, SO_2R^{12} , trifluoromethyl, $NHSO_2R^{12}$, $NHCOR^{12}$, ethylenedioxy, methylenedioxy, $C_{1-6}alkyl$, $C_{1-6}alkoxy$, $C_{1-6}alkylNR^{10}R^{11}$, SR^{12} or $NR^{10}R^{11}$;

25

Het is a heteroaryl ring chosen from pyridine, pyrimidine, pyrazine, pyridazine or triazine and optionally substituted by halogen, amino, hydroxy, cyano, nitro, carboxy, $CONR^{12}R^{13}$, $SO_2NR^{12}R^{13}$, SO_2R^{12} , trifluoromethyl, $NHSO_2R^{12}$, $NHCOR^{12}$, $C_{1-6}alkyl$, $C_{1-6}alkoxy$, SR^{12} or $NR^{10}R^{11}$;

30

R³ is independently hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl;

R⁴ is independently hydrogen, C₁₋₈ alkyl, C₃₋₈ cycloalkyl, arylC₁₋₅alkyl or heteroarylC₁₋₅alkyl, the latter three groups being optionally substituted by one or more
5 halogen, amino, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, SR¹² or NR¹⁰R¹¹;

R⁵ is independently hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl;

R⁶ is independently hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl;

10 R⁷ is independently hydrogen, C₁₋₆ alkyl or C₃₋₆ cycloalkyl;

R⁸ is independently hydrogen, aryl, heteroaryl or C₁₋₆ alkyl optionally substituted with one or more aryl, heteroaryl, halogen, amino, hydroxy, carboxy, CONR¹²R¹³, SO₂NR¹²R¹³,
15 SO₂R¹², NHSO₂R¹², NHCOR¹², C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₁₋₆ alkoxy, SR¹² or NR¹⁰R¹¹;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 in which R¹ is hydrogen or C₁₋₆alkyl and R² is
20 CH₂R⁹ or CH₂CH₂R⁹ where R⁹ is phenyl or a 5- or 6-membered aromatic ring containing one or two heteroatoms and optionally substituted by C₁₋₆alkyl

3. A compound according to claim 1 or 2 in which R¹ and R² form a piperidine, piperazine, pyrrolidine, morpholine, or thiomorpholine ring optionally substituted by
25 CH₂OH, CH₂CH₂OH, hydroxy, CONH₂, phenyl, phenoxy, C(O)-furyl, the latter three groups being optionally substituted by halogen, in particular chloro

4. A compound according to any one of claims 1 to 3 in which R³ is hydrogen.

30 5. A compound according to any one of claims 1 to 4 in which R⁴ is hydrogen.

6. A compound according to any one of claims 1 to 5 in which R⁵ is hydrogen or phenyl optionally substituted by C₁₋₆ alkyl or C₁₋₆ alkoxy.

35 7. A compound of formula (I) selected from:

N~1~- [Cyano(2-methoxyphenyl)methyl]-N~2~- (2-morpholin-4-ylpyrimidin-4-yl)-L-leucinamide

N~1~- [Cyano(2-methoxyphenyl)methyl]-N~2~- (2-piperazin-1-ylpyrimidin-4-yl)-L-leucinamide,

5 N-[Cyano(2-methoxyphenyl)methyl]-N-(2-morpholin-4-ylpyrimidin-4-yl)-L-phenylalaninamide

N~1~- [Cyano(2-methoxyphenyl)methyl]-3-cyclohexyl-N~2~- (2-morpholin-4-ylpyrimidin-4-yl)-L-alaninamide

N-[2-(Benzylamino)pyrimidin-4-yl]-N-(cyanomethyl)-L-phenylalaninamide

10 N-{2-[Benzyl(methyl)amino]pyrimidin-4-yl}-N-(cyanomethyl)-L-phenylalaninamide

N-{2-[4-(4-Chlorophenyl)piperazin-1-yl]pyrimidin-4-yl}-N-(cyanomethyl)-L-phenylalaninamide

N~2~- [2-(Benzylamino)pyrimidin-4-yl]-N~1~- (cyanomethyl)-3-cyclohexyl-L-alaninamide

15 N~2~- {2-[Benzyl(methyl)amino]pyrimidin-4-yl}-N~1~- (cyanomethyl)-3-cyclohexyl-L-alaninamide

N~2~- {2-[4-(4-Chlorophenyl)piperazin-1-yl]pyrimidin-4-yl}-N~1~- (cyanomethyl)-3-cyclohexyl-L-alaninamide

N~1~- (Cyanomethyl)-N~2~- (4-morpholin-4-ylpyrimidin-2-yl)-L-leucinamide

20 N~1~- (Cyanomethyl)-N~2~- (2-morpholin-4-ylpyrimidin-4-yl)-L-leucinamide

N~1~- (Cyanomethyl)-N~2~- [2-(4-hydroxy-4-phenylpiperidin-1-yl)pyrimidin-4-yl]-L-leucinamide

N~1~- (Cyanomethyl)-N~2~- {2-[methyl(pyridin-3-ylmethyl)amino]pyrimidin-4-yl}-L-leucinamide

25 N~2~- {2-[Benzyl(methyl)amino]pyrimidin-4-yl}-N~1~- (cyanomethyl)-L-leucinamide

N~2~- {2-[4-(4-Chlorophenyl)piperazin-1-yl]pyrimidin-4-yl}-N~1~- (cyanomethyl)-L-leucinamide,

N~2~- {2-[4-(5-Chloropyridin-2-yl)piperazin-1-yl]pyrimidin-4-yl}-N~1~- (cyanomethyl)-L-leucinamide,

30 N~1~- (Cyanomethyl)-N~2~- {2-[methyl(thien-3-ylmethyl)amino]pyrimidin-4-yl}-L-leucinamide

N~1~- (Cyanomethyl)-N~2~- (2-thiomorpholin-4-ylpyrimidin-4-yl)-L-leucinamide

N~1~- (Cyanomethyl)-N~2~- [2-(4-phenylpiperazin-1-yl)pyrimidin-4-yl]-L-leucinamide

35 N~1~- (Cyanomethyl)-N~2~- {2-[2-(hydroxymethyl)piperidin-1-yl]pyrimidin-4-yl}-L-leucinamide

N~1~-(Cyanomethyl)-N~2~-{2-[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]pyrimidin-4-yl}-L-leucinamide

N~1~-(Cyanomethyl)-N~2~-{2-(4-hydroxypiperidin-1-yl)pyrimidin-4-yl}-L-leucinamide

5 N~1~-(Cyanomethyl)-N~2~-{2-[4-(2-furoyl)piperazin-1-yl]pyrimidin-4-yl}-L-N~2~-{2-[3-(Aminocarbonyl)piperidin-1-yl]pyrimidin-4-yl}-N~1~-(cyanomethyl)-L-leucinamide

N~1~-(Cyanomethyl)-N~2~-{2-[methyl(2-pyridin-2-ylethyl)amino]pyrimidin-4-yl}-L-leucinamide

10 N~2~-{2-(4-Benzylpiperidin-1-yl)pyrimidin-4-yl}-N~1~-(cyanomethyl)-L-leucinamide
N~1~-(Cyanomethyl)-N~2~-{2-(4-pyridin-2-ylpiperazin-1-yl)pyrimidin-4-yl}-L-leucinamide

N~1~-(Cyanomethyl)-N~2~-{2-(4-phenylpiperidin-1-yl)pyrimidin-4-yl}-L-leucinamide

15 N~1~-(Cyanomethyl)-N~2~-{2-[4-(2-hydroxyethyl)piperidin-1-yl]pyrimidin-4-yl}-L-leucinamide

N~2~-{2-[4-(3-Chlorophenyl)piperazin-1-yl]pyrimidin-4-yl}-N~1~-(cyanomethyl)-L-leucinamide

N~1~-(Cyanomethyl)-N~2~-{2-(4-phenoxy piperidin-1-yl)pyrimidin-4-yl}-L-leucinamide

20 N~1~-(Cyanomethyl)-N~2~-{2-(3-phenylpyrrolidin-1-yl)pyrimidin-4-yl}-L-leucinamide

N~1~-(Cyanomethyl)-N~2~-{2-{methyl[(3-methylisoxazol-5-yl)methyl]amino}pyrimidin-4-yl}-L-leucinamide

and pharmaceutically acceptable salts thereof.

25

8. A compound of formula (I) as defined in any one of claims 1 to 7 for use in therapy.

9. A pharmaceutical composition which comprises a compound of the formula (I) as defined in any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof and a
30 pharmaceutically acceptable diluent or carrier.

10. A method for producing inhibition of a cysteine protease in a mammal, such as man, in need of such treatment, which comprises administering to said mammal an effective amount of a compound of the present invention as defined in any one of claims 1 to 7 or a
35 pharmaceutically acceptable salt thereof.

11. A method for treating pain, such as neuropathic pain, in a mammal, such as man, in need of such treatment, which comprises administering to said mammal an effective amount of a compound as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.